Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Status:
Completed
Trial end date:
2020-06-29
Target enrollment:
Participant gender:
Summary
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to
one of the standard treatments (radiation and hormones) for men with high-risk prostate
cancer.